首页> 外文OA文献 >Response to lorlatinib on a patient with ALK ‐rearranged non‐small cell lung cancer harboring 1151Tins mutation with uterine metastasis

【2h】

Response to lorlatinib on a patient with ALK ‐rearranged non‐small cell lung cancer harboring 1151Tins mutation with uterine metastasis

机译：对患有Alk -rearranged非小细胞肺癌的患者对患者的响应患有1151吨突变的患者与子宫转移

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Takashi Kobayashi; Shintaro Kanda; Toshirou Fukushima; Takuro Noguchi; Nodoka Sekiguchi; Tomonobu Koizumi;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Response to lorlatinib on a patient with ALK-rearranged non-small cell lung cancer harboring 1151Tins mutation with uterine metastasis [J] . Takashi Kobayashi, Shintaro Kanda, Toshirou Fukushima, Thoracic cancer. . 2021,第16期

机译：对患者对患者的乳酸对患者的反应，患有1151吨突变的子宫转移
2. Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation [J] . Sara Baglivo, Biagio Ricciuti, Vienna Ludovini, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018,第8期

机译：对Lorlatinib在含G1202R突变的重预处理肺腺癌患者中的戏剧反应和同步新的R1192P ALK点突变
3. Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non-small-cell Lung Cancer [J] . Sakakibara-Konishi Jun, Kitai Hidenori, Ikezawa Yasuyuki, Clinical lung cancer . 2019,第5期

机译：在患有ALK重新排列的非小细胞肺癌的患者中洛拉替尼的进展后的蠕动后重新施用
4. Enumeration and ALK Investigation of Circulating Tumor Cells in Non-Small Cell Lung Cancer (NSCLC) Patients Using an Effective In Vivo Technology, the GILUPI CellCollector? [C] . Klaus Luecke, Lukasz Gasiorowski, Stefanie Herold, International Molecular Medicine Tri-Conference. . 2015

机译：使用有效的体内技术（Gilupi Cellcollector
5. Pharmacology Profiles of ALK and FLT3 Kinase Inhibitors against Non-Small-Cell Lung Cancer Cells and Acute Myeloid Leukemia Cells with Cancer Driver Mutations [D] . 森政道 2019

机译：ALK和FLT3激酶抑制剂对非小细胞肺癌细胞和急性髓系白血病细胞的癌症驱动突变的药理作用
6. Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFR mutation [O] . Akihiko Miyanaga, Kumi Shimizu, Rintaro Noro, 2013

机译：EGFR-酪氨酸激酶和ALK抑制剂对EML4–ALK重排的非小细胞肺癌具有EGFR突变共存的作用
7. Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non–small-cell Lung Cancer [O] . Jun Sakakibara-Konishi, Hidenori Kitai, Yasuyuki Ikezawa, 2019

机译：在患者中携带洛拉替尼在患者中患者的克里齐替尼重新施用的反应，伴有ALK重新排列的非小细胞肺癌

Response to lorlatinib on a patient with ALK ‐rearranged non‐small cell lung cancer harboring 1151Tins mutation with uterine metastasis

著录项

引文网络

相似文献

相关主题

期刊订阅